ATX-304
MetabolicAlso known as O304
Evidence tier
Moderate published literature
26 publications over 20 years · trials not yet curated
- Researched since
- 2006
- Publications
- 26
- Mean purity
- —
- Vendors listing
- 0
No indexed vendor publishes certificate records for ATX-304 that this index could read yet, so no purity comparison is possible.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2006 — 20 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
26 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is ATX-304?
A direct pan-AMPK activator (also known as O304), studied preclinically in metabolic and vascular models.
Studied in published research for metabolic and vascular disease, as an AMPK activator.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- NTRK1 knockdown induces mouse cognitive impairment and hippocampal neuronal damage through mitophagy suppression via inactivating the AMPK/ULK1/FUNDC1 pathway — Cell death discovery (2023)
Peer-reviewed article indexed in PubMed, published in Cell death discovery (2023).
- AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching — JCI insight (2025)
Peer-reviewed article indexed in PubMed, published in JCI insight (2025).
- The AMPK activator ATX-304 alters cellular metabolism to protect against cisplatin-induced acute kidney injury — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2024)
Peer-reviewed article indexed in PubMed, published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2024).
- Nicotinohydrazide — Acta crystallographica. Section E, Structure reports online (2007)
Peer-reviewed article indexed in PubMed, published in Acta crystallographica. Section E, Structure reports online (2007).
- 6-Chloro-3-[5-(4-fluoro-phen-yl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl]-2-methyl-4-phenyl-quinoline — Acta crystallographica. Section E, Structure reports online (2010)
Peer-reviewed article indexed in PubMed, published in Acta crystallographica. Section E, Structure reports online (2010).
- O304 is a mitochondrial uncoupler which extends C. elegans lifespan and induces vasorelaxation of rat mesenteric arteries — Chemico-biological interactions (2025)
Peer-reviewed article indexed in PubMed, published in Chemico-biological interactions (2025).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|
Certificate records
No certificate records are indexed. Either none are published, or those published could not be read without an account.